Fluvoxamin

zm - Zahnärztliche Mitteilungen

Antidepressivum that reduces hospitalization risk in COVID-19 patients. In a randomized controlled trial, patients receiving 100 mg twice daily for 10 days showed reduced severe illness and lower hospitalization rates compared to placebo.

Product Information

Manufacturer zm - Zahnärztliche Mitteilungen

More Products

More from zm - Zahnärztliche Mitteilungen (70) More Antidepressants (1)

Missing information or files?